Pelthos Therapeutics (PTHS) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

PTHS · Stock Price

USD 25.03+14.03 (+127.55%)

Market Cap: $84.0M

Historical price data

Market Cap: $84.0MFounded: 2020HQ: San Diego, United States

Sector Ranking#274 in Small Molecule Drugs

Overview

Pelthos Therapeutics is a San Diego-based biopharmaceutical company with a mission to commercialize innovative therapies for patients with unmet dermatological needs. Its core achievement is the FDA approval of ZELSUVMI™ for molluscum contagiosum, complemented by a strategic portfolio of acquired, late-stage topical products. The company's strategy leverages a dual approach: a commercial engine for launching acquired assets and a proprietary NITRICIL™ nitric oxide platform for future internal development, aiming to build a sustainable, revenue-generating dermatology franchise.

DermatologyInfectious Disease

Technology Platform

NITRICIL™ is a proprietary nitric oxide (NO)-based platform that stores gaseous NO on polymers, allowing for controlled, tunable release to achieve targeted antimicrobial and immunomodulatory effects for topical therapies.

Funding History

1

Total raised:$4.5M

Seed$4.5MUndisclosedJun 15, 2022

Opportunities

Pelthos holds first-mover advantage with the only FDA-approved pharmacologic treatment for molluscum contagiosum, a market of ~6 million U.S.

patients.

Its sequential launch strategy for three approved products provides a clear, near-term path to building a multi-indication, revenue-generating dermatology franchise.

Risk Factors

The company faces significant commercial execution risk as it launches its first product in an unproven market.

Financial sustainability depends on successful revenue generation and managing cash burn through multiple concurrent product launches, potentially requiring dilutive financing.

Competitive Landscape

In molluscum, ZELSUVMI™ competes primarily with procedural therapies, holding a unique first-to-market drug advantage. In impetigo and head lice, it faces entrenched generic and branded competitors, requiring effective differentiation and commercial execution to gain market share.